<DOC>
	<DOC>NCT01295697</DOC>
	<brief_summary>The goal of this clinical research study is to find the highest tolerable dose of EZN-2208 that can be given to pediatric patients with Relapsed or Refractory Solid Tumors. The safety of the study drug and its effect on the disease will also be studied.</brief_summary>
	<brief_title>Study of EZN-2208 Pediatric Patients With Solid Tumors</brief_title>
	<detailed_description>Pharmacokinetic (PK) testing of EZN-2208, will be performed for patients who volunteer. PK testing measures the amount of a drug in the body at different time points.</detailed_description>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Patients with histologic verification of malignancy at original diagnosis or relapse. Measurable or evaluable disease Karnofsky score more or equal to 50 for patients &gt;16 years of age and Lansky score more or equal to 50 for patients &lt;16 years of age Patients previously treated with irinotecan will be eligible for this study if they have not had documented progressive disease during treatment with an irinotecancontaining regimen. Adequate hematologic, hepatic, coagulation, renal, and metabolic function Pregnant or breast feeding patients will not be enrolled in this study Patients who are currently receiving other anticancer agents Patients who have an uncontrolled infection Patients requiring cytochrome P450 3A4 enzyme inducing or inhibiting agents</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Patients with non-CNS or CNS tumors</keyword>
	<keyword>Pediatric patients with Relapsed/Refractory Solid Tumors</keyword>
</DOC>